CMS-FDA Breast Cancer and Avastin: FDA Pulls Approval While CMS Pays

Food and Drug Administration (FDA) Commissioner Dr. Margaret Hamburg announced in a 69-page decision that the agency would withdraw the biologic medicine Avastin as a treatment option for women with metastatic breast cancer.??

Avastin (bevacizumab) is an injectable cancer medication manufactured and marketed by Genentech. ?Avastin blocks a protein that is important for the formation of blood vessels and is thought to work by preventing the formation of new blood vessels that feed cancer tumors.?

Commissioner Hamburg?s decision will not affect Avastin?s approved indications for se in colon, lung, kidney, and brain cancers, and Avastin will remain on the market. As a result, physicians will be free to prescribe Avastin off-label for [.....]

By: Thomas Sullivan

Read Full Post: Policy and Medicine

Short URL: http://healthcareroundup.com/?p=79161

Source: http://healthcareroundup.com/2011/12/cms-fda-breast-cancer-and-avastin-fda-pulls-approval-while-cms-pays/

angela davis zombie apocalypse matt moore matt moore national grid andrew luck andrew luck